Related Experiment Video

Updated: Aug 13, 2026

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Six-month isoniazid-rifampin treatment for pulmonary tuberculosis in children

F J Reis1, M B Bedran, J A Moura

  • 1Department of Pediatrics, University of Minas Gerais (UFMG), Brazil.

The American Review of Respiratory Disease
|November 1, 1990
PubMed

Insights

A 6-month daily treatment of rifampin and isoniazid effectively treated childhood pulmonary tuberculosis. This regimen showed excellent clinicoradiologic response and no relapses in children with tuberculosis.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Pulmonology

Background:

  • Childhood pulmonary tuberculosis presents diagnostic challenges.
  • Effective treatment regimens are crucial for pediatric tuberculosis management.

Purpose of the Study:

  • To evaluate the efficacy and safety of a 6-month daily regimen of rifampin and isoniazid for treating primary pulmonary tuberculosis in children.

Main Methods:

  • One hundred seventeen children with pulmonary tuberculosis received daily rifampin (15 mg/kg/day) and isoniazid (10 mg/kg/day) for 6 months.
  • Diagnosis was based on clinical, epidemiological, tuberculin, radiological, and bacteriological/histological criteria.
  • Treatment completion, weight gain, and clinicoradiologic response were assessed.

Main Results:

  • Treatment was completed by 83% of children, with a mean weight gain of 2,145 g.
  • All patients showed excellent clinicoradiologic response and improvement in chest roentgenograms.
  • No relapses occurred during an average follow-up of 21.4 months.

Conclusions:

  • A 6-month daily combination therapy of rifampin and isoniazid is efficacious for treating primary pulmonary tuberculosis in children.
  • This regimen demonstrates excellent outcomes with no observed relapses.
  • The treatment is well-tolerated and effective in improving pediatric tuberculosis cases.

More Related Videos

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients03:47

A Retrospective Study on Endoscopic Surgery for the Treatment of Paravertebral Abscess in Spinal Tuberculosis Patients

Published on: October 25, 2024

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells10:24

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Published on: May 22, 2026

Related Concept Videos

Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...